Stockscreener 앱 받기
161.32
3.54%
5.52
시장 영업 전:
166.00
4.68
+2.90%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine Biosciences stock hits all-time high at 160.31 USD By Investing.com - Investing.com Australia
Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates - simplywall.st
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity - ChartMill
Neurocrine stock soars 61% after InvestingPro Fair Value signal By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations - Investing.com
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 25% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus - Yahoo Finance
MSN Money - MSN
Neurocrine Biosciences Stock On Fire: Up 19% With 10-Day Winning Streak - Trefis
Neurocrine Biosciences Stock 10-Day Winning Spree: Stock Climbs 19% - Trefis
Neurocrine Biosciences stock (US62886E1082): Analysts lift price targets after strong Q1 2026 result - AD HOC NEWS
Neurocrine Is Maintained at Overweight by JP Morgan - Moomoo
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus - TradingView
Neurocrine Friedreich ataxia asset granted FDA orphan status - MSN
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Neurocrine Biosciences, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Earnings Beat: Neurocrine Biosciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $185 - Moomoo
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences Stock Rockets 17% With 9-Day Winning Streak - Trefis
Neurocrine Biosciences Stock 9-Day Winning Spree: Stock Climbs 17% - Trefis
Neurocrine Is Maintained at Buy by Truist Securities - Moomoo
Neurocrine (NBIX) Q1 2026 Earnings Transcript - AOL.com
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Neurocrine Biosciences Q1 2026 earnings preview - MSN
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability - Sahm
Neurocrine Biosciences Stock 8-Day Winning Spree: Stock Climbs 15% - Trefis
Research Alert: CFRA Keeps Hold Rating On Shares Of Neurocrine Biosciences Inc. - 富途牛牛
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside - Seeking Alpha
Oppenheimer Adjusts Price Target on Neurocrine Biosciences to $230 From $220, Maintains Outperform Rating - Moomoo
Truist raises Neurocrine Bio stock price target on strong sales By Investing.com - Investing.com Canada
Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains? - Yahoo Finance
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia - BioSpace
Oppenheimer raises Neurocrine Bio stock price target on strong results By Investing.com - Investing.com India
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
New CRENESSITY guidance on cutting high steroid doses in CAH - Stock Titan
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY - StreetInsider
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript - Insider Monkey
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Neurocrine Biosciences (NBIX) Valuation Check After New Long Term CRENESSITY Phase 3 Data - Sahm
Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $200 - Moomoo
Neurocrine Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Neurocrine Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Neurocrine Biosciences surges 8% as INGREZZA sales drive better-than-expected Q1 results - Investing.com Nigeria
Neurocrine Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NBIX) 2026-05-05 - Seeking Alpha
Neurocrine Q1 2026 slides: revenue surges 44% on dual-product strength - Investing.com
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat By Investing.com - Investing.com Australia
3.68%
0.38%
자본화:
|
볼륨(24시간):